Perioperative Care
Incidence and treatment of residual neuromuscular blockade & NMB monitoring technologies
Incidence of residual paralysis and its clinical impact

Whenever a neuromuscular blocking drug is being used, block must be monitored quantitatively. The people we got to convert are the consultant anesthetists who have been working for years, who are less likely to change their practice now. Prof. Hunter

Treatment of residual block: a look at the practice

If you do not monitor your patient perioperatively in the PACU you have 3 times more the risk of residual paralysis. There is a clear demonstration of the need of neuromuscular monitoring whatever reversal agent is used. Prof Meistelman
Neuromuscular block monitoring: the added value and technological differences

I recommend electromyography (EMG) for a clear decision making process based on neuromuscular monitoring. TOF>=90 measured with AMG does not guarantee complete recovery. Prof Blobner
Watch the full replay of our
Perioperative Care Live TV!
The audience enjoyed the interactivity of the live session and asked a lot of questions to our speakers. Not all of them could be answered live during the show, so they are now accessible here!

Prof. Jennifer Hunter
University of Liverpool, United Kingdom

Honorary life member ESA. Gold medal of royal college of anaesthetists, AAGBI awards chief editor of BJA. PK PD of neuromuscular blocking drugs and their antagonists. The health economics of new reversal agents.

Prof. Claude Meistelman
CHU Brabois, Nancy, France
Member ESA and president of research committee. SFAR member and active in reviewing papers . NMB Agents, pharmacology of NMBA in padiatrics analgesia and sedation in ICU

Prof. Manfred Blobner
Technical University of Munich, Germany
ESA and DAC member. Responsability for reviewing papers and very active publisher NMB monitoring technology expert